United States · Markets & Finance · Investor's Business Daily

Teva, Already Up 26% This Year, Surges Again On First-Of-Its-Kind Approval

Published by Investor's Business Daily · United States 1 d ago

Teva stock surged Friday after the FDA approved its schizophrenia drug, a once-monthly injectable treatment for the disease.

Read the full article on Investor's Business Daily Sign in to save

MediaNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.investors.com)

Also worth reading

Business Insider

I moved my family from Australia to New York City 12 years ago. It's led to some very expensive regrets.

China passenger vehicle retail market slumps 24% in September

CFTC Draws the Line Between Prediction Markets and Gambling in New Rules

Petra Power looks to modernize energy for data centers and defense vehicles

Kasai, Klarity and 8 other baby names surging in America

JPMorgan makes bullish call in fixed income space, suggests it's a once in a generation opportunity